Non-invasive evaluation of botulinum-A toxin treatment efficacy in children with refractory overactive bladder
| Autor: | Murat Uçar, Ahsen Karagözlü Akgül, Emin Balkan, Cem Yücel, Ayse Parlak, Nizamettin Kılıç |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
Nephrology medicine.medical_specialty Time Factors Adolescent Urology Dysfunctional voiding 030232 urology & nephrology Urination Urinary incontinence 03 medical and health sciences 0302 clinical medicine Refractory Internal medicine medicine Humans Botulinum Toxins Type A Child Retrospective Studies Botulinum a toxin Dose-Response Relationship Drug Urinary Bladder Overactive business.industry Non invasive medicine.disease Treatment efficacy Administration Intravesical Treatment Outcome Neuromuscular Agents Overactive bladder 030220 oncology & carcinogenesis Female medicine.symptom business Follow-Up Studies |
| Zdroj: | International Urology and Nephrology. 50:1367-1373 |
| ISSN: | 1573-2584 0301-1623 |
| DOI: | 10.1007/s11255-018-1926-6 |
| Popis: | We aimed to evaluate the efficacy and safety of intravesical onabotulinum toxin A (onaBoNTA) injections for the treatment of children diagnosed with refractory overactive bladder (OAB) by using non-invasive methods. A total of 31 pediatric patients with a mean age of 10.2 years received intravesical onaBoNTA injection at the dose of 10 U/kg (max: 200 U). Twenty-one patients who failed to respond to the first injection, received second injection 6 months after the first one. The patients were retrospectively evaluated after the 1st and the 2nd injections by means of standardized questionnaire forms and voiding diary records. In the 6-month follow-up, 10 patients (32.2%) were determined to have full response after the first injection. The number of patients with partial response and no response were found to be 15 (48.4%) and 6 (19.4%), respectively. The mean value of Dysfunctional Voiding and Incontinence Symptom Score (DVISS) of the patients with full response was 8.5 before the injection, which decreased to 1 at 6-month follow-up and to 0.5 at 12-month follow-up (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink